Pipeline

^aApproved in more than 40 countries and regions, including but not limited to the U.S. and European Union.
^bPrior treatment with 3 or more kinase inhibitors, including imatinib. 
^cApproved in the U.S., and European Union.
^dTGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
^eDeveloped in collaboration with Deciphera’s parent company, Ono Pharma. 
^fSapablursen is under license agreement from Ionis Pharmaceuticals to Ono Pharma and its affiliates.

1L, first line; 2L, second line; BTK, Bruton tyrosine kinase; CD3, cluster of differentiation 3; cGVHD, chronic graft versus-host disease; CSF1R, colony-stimulating factor 1 receptor; EP4, prostaglandin E receptor 4; GCN2, general control nonderepressible 2; GIST, gastrointestinal stromal tumor; KIT, KIT proto-oncogene receptor tyrosine kinase; PD-1, programmed cell death protein 1; PDGFRA, platelet-derived growth factor receptor alpha; PCNSL, primary central nervous system lymphoma; R/R, relapsed or refractory; S1P5, sphingosine-1-phosphate receptor 5; TGCT, tenosynovial giant cell tumor; TKI, tyrosine kinase inhibitor; TMPRSS6, transmembrane protease serine 6; ULK, Unc-51–like autophagy activating kinase

The safety and efficacy of the agents for the indications under investigation have not been established.